ANAVEX RECEIVES APPROVAL TO COMMENCE PHASE I CLINICAL TRIAL IN ALZHEIMER’S DISEASE
Anavex Life Sciences Corp. (“Anavex”)
(OTCBB: AVXL) today announced that its clinical trial application (CTA)
for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease,
has been approved by the German regulatory health authority, BfArM.
The Phase I trial of ANAVEX 2-73, which includes testing in healthy
human volunteers, will commence immediately. In this Phase I program
Anavex will assess the safety, maximally tolerated dose,
pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
“We are excited to have received the German regulatory health
authority’s approval to take ANAVEX 2-73 into the clinic. This marks a…
View full post on Live News from PR-USA.net
Recent Blog Posts:
Popular Blog Posts:
Subscribe to our RSS